Betta Pharmaceuticals (SHE:300558) obtained exclusive general distribution rights for the recombinant human coagulation factor VIII-Fc fusion protein for injection (FRSW117) in the Greater China region, according to a Sunday filing.
The Chinese pharmaceutical company, through unit Zhejiang Betta Pharmaceutical Sales, signed the commercial cooperation agreement with Hangzhou Shens Biopharmaceutical.
FRSW117, which recently completed phase III clinical trials, was developed to treat patients with hemophilia A.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments